Search research articles
Contact Us
Filters
Showing results (131-140 of 212) with videos related to
Page
of 22
Sort By:
Haematologica
|
July 29, 2021
Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin
Chen Wang, Kathy L McGraw, Amy F McLemore, et al.
Blood Advances
|
February 16, 2021
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
Anthony M Hunter, Rami S Komrokji, Seongseok Yun, et al.
British Journal of Haematology
|
February 22, 2011
Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes
Lubomir Sokol, Gisela Caceres, Stefano Volinia, et al.
Leukemia Research
|
December 8, 2005
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Francis J Giles, William T Bellamy, Zeev Estrov, et al.
Leukemia
|
November 26, 2022
Biological drivers of clinical phenotype in myelofibrosis
John Mascarenhas, Hélène F E Gleitz, Helen T Chifotides, et al.
Oncotarget
|
September 30, 2015
TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes
Kathy L McGraw, Thomas Cluzeau, David A Sallman, et al.
Cancer Research
|
May 20, 2016
Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41
Ashley A Basiorka, Kathy L McGraw, Leentje De Ceuninck, et al.
Journal of Hematology & Oncology
|
March 7, 2012
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
Yuka Sugimoto, Mikkael A Sekeres, Hideki Makishima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 23, 2019
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Kendra Sweet, Rami Komrokji, Eric Padron, et al.
Leukemia Research
|
July 30, 2019
Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC)
Seongseok Yun, Rohit Sharma, Onyee Chan, et al.
Page
of 22
Search research articles
Search
Showing results (131-140 of 212) with videos related to
Sort By:
Page
of 22
Haematologica
|
July 29, 2021
Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin
Chen Wang, Kathy L McGraw, Amy F McLemore, et al.
Blood Advances
|
February 16, 2021
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
Anthony M Hunter, Rami S Komrokji, Seongseok Yun, et al.
British Journal of Haematology
|
February 22, 2011
Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes
Lubomir Sokol, Gisela Caceres, Stefano Volinia, et al.
Leukemia Research
|
December 8, 2005
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Francis J Giles, William T Bellamy, Zeev Estrov, et al.
Leukemia
|
November 26, 2022
Biological drivers of clinical phenotype in myelofibrosis
John Mascarenhas, Hélène F E Gleitz, Helen T Chifotides, et al.
Oncotarget
|
September 30, 2015
TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes
Kathy L McGraw, Thomas Cluzeau, David A Sallman, et al.
Cancer Research
|
May 20, 2016
Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41
Ashley A Basiorka, Kathy L McGraw, Leentje De Ceuninck, et al.
Journal of Hematology & Oncology
|
March 7, 2012
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
Yuka Sugimoto, Mikkael A Sekeres, Hideki Makishima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 23, 2019
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Kendra Sweet, Rami Komrokji, Eric Padron, et al.
Leukemia Research
|
July 30, 2019
Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC)
Seongseok Yun, Rohit Sharma, Onyee Chan, et al.
Page
of 22